Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated Marrow Infiltrating Lymphocytes in Multiple Myeloma
NCT00566098Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2007
- Primary completion
- Jun 2014
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of marrow-infiltrating lymphocytes in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Hematopoietic Engraftment at 1 year, Disease Response at 2 years and 2 more. Started Nov 2007; status: completed.
02
Drugs
marrow-infiltrating lymphocytes
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00566098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566098.